Clinical Trial Update: Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA) [Phase 1, Phase 2]

View source ↗

Summary

This entry describes a Phase 1/2 clinical trial of an NY-ESO-1–based therapeutic vaccine with the MPLA adjuvant, evaluated in melanoma, ovarian cancer, and lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Melanoma
• Ovarian Cancer

Drugs mentioned

• Monophosphoryl Lipid A (MPLA) adjuvant (monophosphoryl lipid A)
• NY-ESO-1 therapeutic vaccine

Snippet

Sponsor: Instituto de Investigação em Imunologia | Conditions: Cancer., Melanoma. | Phase 1, Phase 2 | Status: UNKNOWN